1-4 of 4
Wallace Y Langdon, PhD
Close
Sort by
Journal Articles

The FLT3 Inhibitor Quizartinib Provides a Novel Strategy to Inhibit Chemotherapy-Induced Myelosuppression

Wallace Y Langdon, PhD, Samuel J Taylor, PhD, Johanna M Duyvestyn, BSc(Hons), Samantha A Dagger, BSc(Hons), George S. Vassiliou, MD PhD, Carolyn s. Grove, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4041.
https://doi.org/10.1182/blood.V128.22.4041.4041
Published: 2016
Journal Articles

Control of JAK2 Ubiquitination and Stability By CBL Family E3 Ubiquitin Ligases in Hematopoietic Stem/Progenitor Cells and Myeloid Malignancies

Kaosheng Lyu, PhD, Jing Jiang, PhD, Wei An, PhD, Wallace Y Langdon, PhD, Hamid Band, MD PhD, Wei Tong, PhD
Journal: Blood
Blood (2016) 128 (22): 723.
https://doi.org/10.1182/blood.V128.22.723.723
Published: 2016
Journal Articles

FLT3 Inhibitor AC220 Is a Potent Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice

Wallace Y Langdon, PhD, Samantha A Dagger, Samuel J Taylor, Christine B F Thien, PhD, Matthew E Wikstrom, PhD
Journal: Blood
Blood (2011) 118 (21): 642.
https://doi.org/10.1182/blood.V118.21.642.642
Published: 2011
Journal Articles

Cbl-Deficient Mice Display Erythropoietin Hypersensitivity and Enhanced Phosphorylation of Protein Kinase B/Akt.

Terri D. Richmond, BSc, Monica L. Bailey, BSc, Wallace Y. Langdon, PhD, Dwayne L. Barber, PhD
Journal: Blood
Blood (2005) 106 (11): 3137.
https://doi.org/10.1182/blood.V106.11.3137.3137
Published: 2005